← Human Trials & Peer-Reviewed Studies
Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age.
Plain-language guide to PMID 11207640 (2001): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 11207640
- Journal
- Clinical endocrinology
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Sas T et al. (7 authors)
- DOI
- 10.1046/j.1365-2265.2001.01178.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
To assess possible side-effects of long-term continuous growth hormone (GH) treatment on carbohydrate (CH) metabolism in children with short stature born small for gestational age.
Who Took Part
The age groups tagged for this paper are children, both men and women.
Seventy-eight children with short stature (height SD-score < - 1.88) born small for gestational age (birth length SD-score < - 1.88) being all prepubertal with a mean (SD) chronological age of 7.3 (2.2) years before start of treatment.
How the Study Was Run
The researchers set it up as a randomized, double-blind and multicenter study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
More than one site took part, so the participants came from several places.
What Was Measured
The subject headings attached to it are Area Under Curve, Blood Glucose, Body Mass Index, Carbohydrate Metabolism, Glucose Tolerance Test, Glycated Hemoglobin and Growth Disorders.
What This Means in Plain Language
The paper is a randomized, double-blind and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 13 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2001 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.